Tonix Pharmaceuticals Holding Investor Presentation — April 2022

Document content

© 2022 Tonix Pharmaceuticals Holding Corp.INVESTOR

Version P0347 April 12, 2022 (Doc 0992)2

© 2022 Tonix Pharmaceuticals Holding Corp.CAUTIONARY NOTE ON FORWARD- LOOKING STATEMENTS

Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations

or results are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. These forward -looking statements are based on Tonix’s current expectations

and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward -looking statements. These factors include, but are not limited to, the

risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID -19 pandemic; risks related to the timing and progress of clinical

development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. The

forward-looking statements in this presentation are made as of the date of this presentation, even if subsequently

made available by Tonix on its website or otherwise. Tonix does not undertake an obligation to update or revise any forward-looking statement, except as required by law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports and current reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.3

© 2022 Tonix Pharmaceuticals Holding Corp.ADVANCING THE SCIENCE AND UNDERSTANDING OF DISEASES

by developing innovative therapies that improve population health

by focusing on unmet needs in patient careWHAT WE DO

Using our integrated development engine, we advance innovative

programs across multiple therapeutic areas into the clinic while maximizing asset potential OUR MISSION

© 2022 Tonix Pharmaceuticals Holding Corp.CNS PORTFOLIO

ADHD = attention-deficit hyperactivity disorder; FM = fibromyalgia; IND = investigational new drug; PASC = post -acute sequelae of COVID -19; PTSD = posttraumatic stress disorder.PIPELINE: